IDEAS home Printed from
MyIDEAS: Log in (now much improved!) to save this article

¿A quién beneficia el comercio paralelo de medicamentos en la Unión Europea?

Listed author(s):
  • Costa-Font, Joan

    (London School of Economics, Reino Unido, y CAEPS, Universitat de Barcelona)

  • Kanavos, Panos

    (CAEPS, Universitat de Barcelona)

Registered author(s):

    Parallel trade is a legal movement (arbitrage) of goods from one country where the product is first sourced and protected by intellectual property rights to another one but without the warranty of the manufacturer company. This phenomenon takes place as a result of the coexistence of the principle of “free movement of goods” and the subsidiary of national government in social policy affairs. This paper empirically examines whether drug parallel trade in three European Union counties has exerted any effect on prices, and undertaken a distribution of the effect of parallel trade in its stakeholders. Our results suggest that there are very moderate effects of parallel trade on drug prices. The main beneficiaries of parallel trade are parallel importers themselves who bring negligible savings to the health system are moderate, unlikely to overcome the induced costs to drug innovation.// El comercio paralelo constituye un movimiento legal (arbitraje comercial) de productos de un país donde éstos se han puesto en circulación a otro país sin la autorización y la garantía del que posee los derechos de propiedad intelectual del producto. Este fenómeno se deriva de la aplicación del principio de subsidiariedad que lleva asociado la existencia de diferentes sistemas de regulación de precios y el de libre movilidad de bienes. En este artículo examinamos las tendencias de precios y penetración de medicamentos paralelamente importados respecto al precio del producto en el país de destino (beneficios de una mayor competencia) en 2002. En segundo lugar, establecemos una descomposición empírica de los efectos del comercio paralelo de medicamentos en los tres mercados principales de la Unión Europea en los diferentes agentes de la cadena del medicamento. Los resultados no siguieren pruebas de un efecto competitivo del comercio paralelo. Por otra parte, se observa que los principales beneficiarios son los propios importadores paralelos en la medida que el comercio paralelo genera ahorros muy limitados en la factura de los sistemas de salud, que difícilmente superan los perjuicios en la innovación farmacéutica.

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

    File URL:
    Download Restriction: no

    Article provided by Fondo de Cultura Económica in its journal El Trimestre Económico.

    Volume (Year): LXXVI (2) (2009)
    Issue (Month): 302 (abril-junio)
    Pages: 331-347

    in new window

    Handle: RePEc:elt:journl:v:76:y:2009:i:302:p:331-347
    Contact details of provider: Web page:

    Order Information: Postal: Order print issues directly in our web page or with Guadalupe Galicia at Fondo de Cultura Económica, El Trimestre Económico, Carretera Picacho Ajusco 227, 6° piso,Col. Bosques del Pedregal, CP 14738, Tlalpan, Ciudad de México
    Web: Email:

    No references listed on IDEAS
    You can help add them by filling out this form.

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    When requesting a correction, please mention this item's handle: RePEc:elt:journl:v:76:y:2009:i:302:p:331-347. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Rosa María González Mejía)

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.